Company news
Hunan Fangsheng Pharmaceutical Co., Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
(603998)"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Receipt of the Drug Clinical Trial Approval Notice for Innovative TCM R&D Project
November 2, 2026
(603998)"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Progress of Transfer of Certain Equity Interests in a Controlled Subsidiary and Introduction of Strategic Investors
November 2, 2026
(603998)"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Change of Drug Manufacturing License
November 2, 2026
(603998)"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Report for Q3 2026
October 28, 2026
(603998)"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on the Profit Distribution Plan for Q3 2026
October 28, 2026
(603998)"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Resolutions of the 7th Meeting of the 6th Board of Directors
October 28, 2026
(603998)"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Operating Data for the First Three Quarters of 2026
October 28, 2026
(603998)"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Acquisition of Pre-Clinical Trial Technology and Results for an Innovative TCM by Controlled Subsidiary and Related Party Transaction
October 28, 2026
(603998)"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Receipt of Drug Registration Certificate for Iguratimod Tablets
October 23, 2026
(603998)"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Convening the Q3 2026 Performance Briefing
October 22, 2026
(603998)"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Receipt of Drug Registration Certificate for Cobamamide Capsules
October 16, 2026
(603998)"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
October 15, 2026
(603998)"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Notice on Convening the 2nd Extraordinary General Meeting in 2026
September 29, 2026
Announcement on Resolutions of the 6th Extraordinary Meeting of the 6th Board of Directors in 2026
September 29, 2026
Announcement on Progress of Transfer of Certain Equity Interests in a Controlled Subsidiary and Introduction of Strategic Investors
September 22, 2026
Announcement on Implementation of Dividend Distribution for the First Half of 2026
September 6, 2026
Announcement on Outline of the 2026 Semi-annual Performance and Cash Dividend Briefing
August 31, 2026
Announcement on Election of Employee Directors and Adjustment of the Remuneration and Appraisal Committee Members
August 28, 2026
Announcement on Resignation of Director and Deputy General Manager
August 26, 2026
Announcement on Progress of the Company's Acquisition of Pharmaceutical Production Technology
August 25, 2026
Announcement on Convening the 2026 Semi-annual Performance and Cash Dividend Briefing
August 20, 2026
Announcement on Proposed Selection of the Company's Products in the 12th Batch of the National Organized Centralized Volume-Based Drug Procurement
August 3, 2026
Announcement on Progress in Signing the Project Repurchase Agreement
July 28, 2026
Announcement on Resolutions of the 4th Extraordinary Meeting of the 6th Board of Directors in 2026
July 20, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
July 15, 2026
Announcement on Inclusion of the Company's Main Products in the "National Essential Medicines List (2026 Edition)"
July 10, 2026
Announcement on Change of "Drug Manufacturing License"
July 9, 2026
Announcement on Proposed Withdrawal from an M&A Fund and Related Party Transactions
June 29, 2026
Announcement on Progress in the Sale of Partial Equity in Investment Projects by the M&A Fund Participated in and Established by the Company
June 25, 2026
Announcement on Progress in Transferring Partial Equity of Holding Subsidiaries and Introducing Strategic Investors
June 22, 2026
Announcement on Resolutions of the 2nd Extraordinary Meeting of the 6th Board of Directors in 2026
June 8, 2026
Announcement on Progress in Drug Marketing Authorization Transfer
June 1, 2026
Announcement on Implementation of Dividend Distribution for 2025
May 24, 2026
Announcement on Release of Pledge of Partial Shares of Controlling Shareholders
May 19, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 15, 2026
Announcement on Proposed Inclusion of Company Products in the Centralized Volume Procurement of National Chinese Patent Medicine Procurement Alliance
May 6, 2026
Announcement on Obtaining Summary Report of Phase III Clinical Trial for Pediatric Jingxing Anti-tussive Granules in Adults with Acute Tracheobronchitis (Syndrome of Wind-cold Transformation into Heat)
April 28, 2026
Announcement on Outline of the 2025 Annual and Q1 2026 Performance Briefing
April 27, 2026
2025 Annual Report
April 24, 2026
Announcement on Convening Performance Briefing for 2025 and Q1 2026
April 17, 2026
Announcement on Obtainment of the "Drug Registration Certificate" for Silapage Tablets
March 23, 2026
Announcement on Obtaining Drug Registration Certificate for Bisoprolol Amlodipine Tablets
March 4, 2026
Announcement on Continuation of Procurement for Products Selected in Centralized Procurement Agreements Upon Expiration of Agreement Period
March 2, 2026
Announcement on Soliciting Investor Opinions on Matters Related to 2025 Profit Distribution
February 27, 2026
Announcement on Pledge of Partial Shares of Controlling Shareholder
February 11, 2026
Announcement on Its Holding Subsidiary Obtaining the Drug Production License
February 5, 2026
Announcement on Obtainment of the "Drug Registration Certificate" for Loxoprofen Sodium Cataplasm
January 25, 2026
Announcement on Re-recognition of Wholly-owned Subsidiaries as High-tech Enterprises
January 22, 2026
Announcement on the Inspection Results of the Company's Transfer of Raw Material Production
January 11, 2026
Announcement on Special Dividend in 2025
January 5, 2026